Trellis Bioscience, Inc. discovers and develops novel human antibody therapeutics as treatments for infectious disease and oncology indications. The firm is developing human mAb therapies for bacterial and viral infections, and cancer indications, One is for the treatment of respiratory syncytial virus (RSV) infections that aims to provide superior post-infection treatment over the currently marketed mAb by combining antiviral and anti-inflammatory activity. The other is a first-in-class treatment for drug-resistant bacterial infections due to formation of bacterial biofilms, which works by disrupting the biofilm to resensitize bacteria to conventional antibiotics, with activity spanning Gram-positive to Gram-negative bacterial species, including MRSA and Acinetobacter baumanni. This work will help deliver TrellisÂ’ antibody treatment for RSV, a leading cause of lower respiratory tract disease in young children as well as their broad-spectrum biofilm disruptor human antibody for reducing the antibiotic resistance that is associated with biofilm formation.
